Patent · US Active

Combination therapy for cancer treatment

US12220420B2 · kind B2 · utility

0Cited by
49References
21Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 3, 2017
Grant dateFeb 11, 2025
Priority date
Expiry dateMay 3, 2037

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P35/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A method of treating cancer in a subject includes administering at least one active agent including one or more of a thioredoxin reductase inhibitor and a glutathione depleting agent, and administering a pentaaza macrocyclic ring complex corresponding to formula (I) below:

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.